Print Icon

Next Generation Proteomics Highlights

Dear Subscriber, 

We are excited to share our latest highlights and advances in next-generation proteomics:

Kristina Beeler, PhD is Biognosys’ new Chief Business Officer

We are excited to announce the appointment of Kristina Beeler, PhD as CBO. She will be leading the company’s global commercial and business development activities for the contract research business. Her key focus will be the market expansion in the US and strengthening the commercial activities to meet the growing demand for proteomics in large-scale clinical studies.

The Power of LiP-MS Technology for Drug Discovery

Biognosys’ Limited Proteolysis Mass Spectrometry (LiP-MS) technology uses the power of proteomics to validate drug targets, understand mechanisms of action, and anticipate potential off-target effects. Read more on how proteomics can take the uncertainty out of the drug discovery journey in this Technology Networks article.

LiP-MS Drug Target Deconvolution Application Note

Target identification and validation are key challenges in drug discovery. Limited Proteolysis Mass Spectrometry (LiP-MS) is a robust, reliable way to identify on- and off-target binding effects throughout the proteome. Biognosys’ Drug Target Deconvolution service utilizes its unique, patented LiP-MS technology to help optimize and de-risk the drug discovery journey.

Advances in Immuno-oncology Biomarker Discovery Research

Next-generation proteomics can be integrated with clinical outcome data to predict which patients will respond or develop side effects from immunotherapy. The highlights from major oncology conferences about our biomarker discovery research in oncology are covered in this GenomeWeb / Precision Oncology News article.

Unravelling Protein Signatures for the Future of Personalized Medicine

Next-generation proteomics uncovers blood plasma biomarkers for immunotherapy response and side effects in lung cancer patients. Check out our AACR 2021 virtual poster presentation by Kamil Sklodowski in collaboration with Institut Curie and download the poster from our website.

Parker Institute for Cancer Immunotherapy PRINCE Trial 

The Parker Institute for Cancer Immunotherapy (PICI), the winner of last year’s Biognosys Grant Program, presented promising first results of the PRINCE trial. We have worked closely with PICI to reveal proteomic signatures associated with clinical outcomes in metastatic pancreatic cancer patients. Together, we plan to share the results of our proteomic analysis at a future conference. 

Visit our website to learn more about how we can support your proteomics research and stay tuned for future Proteomics Highlights:

Best regards, 
The Biognosys Team

Can't read or view images? View in Browser

Want to edit your profile? Update Profile

Not interested? Unsubscribe

No more? Opt Out from Organization